Sexual steroids and hemostasis;Sexualsteroide und hämostase

Hamostaseologie

Volumn 21, Issue 1, 2001, Pages 30-34

  Graser Th ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Estrogens; Fibrinolysis; Hormone replacement therapy; Oral contraceptives; Progestins; Sexual steroids

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; ETHINYLESTRADIOL; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN S; PROTHROMBIN; SEX HORMONE; TISSUE PLASMINOGEN ACTIVATOR;

AGE; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; DOSE RESPONSE; FIBRINOLYSIS; GENETIC PREDISPOSITION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; ORAL CONTRACEPTION; RISK FACTOR; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 18744423776     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619502     Document Type: Article

References (33)

1. Comparison of two triphasic contraceptives with different progestogens: Effects on metabolism and coagulation proteins
2. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen
3. Changes in coagulation and fibrinolysis with low dose oral contraceptives
4. Oral contraceptives and thrombo-embolic disease: Effects of lowering estrogen content
5. Coagulation activation following estrogen administration to postmenopausal women
6. Antithrombin III and the estrogen content of combined oestro-progestogen contraceptives
7. Risk of venous thromboembolism in users of hormone replacement therapy
8. Hemostasis profile in women taking low-dose oral contraceptives
9. Inherited antithrombin III deficiency causing thrombophilia
10. Oral contraceptives and the hemostatic system
11. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
12. The risk of venous thromboembolic disease among German women using oral contraceptives: A database study
13. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives
14. Prospective study of exogenous hormones and risk of pulmonary embolism
15. Epidemiological assessment of cardiovascular effects of hormonal contraception
16. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism
17. Cardivascular risks associated with oral contraceptives
18. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood
19. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
20. Oral contraceptives (OC) and venous thromboembolism: A case-control study
21. Hemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen
22. Oral contraceptives and thrombotic risk: A critical overview
23. Steroidal contraceptives and changes in individual plasma phospholipids: Possible role in thrombosis
24. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women
25. Oral contraceptives and cardiovascular disease: A critique of epidemiological studies
26. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
27. Hemostatic system changes induced by 50 μg and 30 μg estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel
28. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboemboric disorders: An international case-control study
29. First-time use of newer oral contraceptives and the risk of venous thromboembolism
30. Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives
31. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women
32. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease